|Bid||58.27 x 800|
|Ask||58.28 x 800|
|Day's Range||57.68 - 58.63|
|52 Week Range||49.96 - 70.05|
|Beta (3Y Monthly)||1.16|
|PE Ratio (TTM)||260.22|
|Earnings Date||Oct 25, 2018|
|Forward Dividend & Yield||1.60 (2.78%)|
|1y Target Est||61.59|
New regulation could force drug companies to disclose their prices on TV ads. Yahoo Finance's Seana Smith, Zack Guzman and Sibile Marcellus discuss.
- Growing body of evidence, including real-world studies, points to the clinical significance of anti-citrullinated protein antibody as a biomarker of poor prognosis in pati
Nektar Therapeutics (NKTR) is focused on developing a strong pipeline of product candidates that utilize its polymer conjugate technology platforms. Its research pipeline includes investigational drugs for cancer, autoimmune diseases, and chronic pain. Nektar Therapeutics generated revenues of $1.09 billion in the second quarter of 2018.
A look at who's moving, who's growing and who's dealing in the Bay Area's health care and life sciences space.
Zacks.com highlights: Bristol-Myers Squibb, Celanese, Ternium S.A. and Mettler-Toledo International
Novartis (NVS) is set to release its third quarter of 2018 earnings results on October 18. Analysts are estimating EPS of $1.31 and revenues of $13.02 billion. Novartis, one of the largest pharmaceutical companies by revenue, specializes in the development, manufacturing, and marketing of healthcare products.
AbbVie (ABBV) signs licensing deal with Sandoz, the generic arm of Novartis. J&J (JNJ) gains FDA approval for label expansion of its blood thinner, Xarelto.
Bristol-Myers (BMY) enters a clinical trial collaboration with Compugen and will make a $12-million equity investment in the latter.
Bristol-Myers Squibb Co said on Friday that its blockbuster cancer drug Opdivo failed to meet the main goal in a late-stage trial on patients with a type of lung cancer, whose condition had relapsed after chemotherapy. The drug failed to extend overall survival in patients suffering from small cell lung cancer, an aggressive form of the disease, when compared to patients already on chemotherapy. Opdivo has already been approved to treat several forms of cancer, including skin and lung cancer.
Bristol-Myers Squibb Co. said Friday a late-stage trial of a treatment for small cell lung cancer failed to meet its main goal. The drug company said the Phase 3 study called CheckMate-331 evaluating its opdivo in patients with the disease who relapsed following platinum-based chemotherapy failed to meet its primary endpoint of overall survival. "Small cell lung cancer is a highly aggressive disease in which significant unmet need remains," said Sabine Maier, development lead, thoracic cancers, at Bristol-Myers Squibb. "We are focused on researching innovative oncology therapies to improve outcomes for patients with lung cancer." Shares were slightly higher premarket, but have fallen 6.1% in 2018, while the S&P 500 has gained 2.1%.
Bristol-Myers Squibb Company today announced topline results from the Phase 3 CheckMate -331 study evaluating Opdivo versus the current standard of care, topotecan or amrubicin , in patients with small cell lung cancer who relapsed following platinum-based chemotherapy.
Johnson & Johnson (JNJ) plans to report its third-quarter earnings on October 16. Wall Street analysts expect JNJ to register adjusted EPS of $2.03 in the third quarter, representing YoY (year-over-year) growth of ~6.7%. In comparison, the company reported second-quarter adjusted EPS of $2.10.